Clinical Evaluation of an Acer truncatum Seed Oil–Phosphatidylserine Complex for Neurodevelopment Support

Abstract

Background: Acer truncatum seed oil is a nervonic-acid–rich botanical lipid source with theoretical relevance to myelin-oriented neurodevelopment, while phosphatidylserine (PS) is a membrane phospholipid with a substantially larger human evidence base in cognition and attention. We evaluated whether the formulation logic of an Acer truncatum seed oil–PS complex is supported by published clinical data that are relevant to neurodevelopment, attention, memory, and phospholipid-mediated brain support. Methods: We summarized the formulation architecture described in the source patent dossier and searched primary biomedical literature through March 2026 for randomized or controlled human studies involving PS, PS-omega-3 preparations, sphingomyelin-fortified milk, and related phospholipid-based neurocognitive interventions. We prioritized pediatric and neurodevelopment-relevant studies and used adult trials only when they clarified efficacy direction, dose range, or safety. Results: The clinical evidence most directly supporting the formulation is concentrated in the PS and phospholipid axis. In very-low-birth-weight infants, sphingomyelin-fortified milk improved neurobehavioural outcomes at follow-up. In children with ADHD, soy-derived PS improved ADHD symptoms and short-term auditory memory, and PS-omega-3 reduced hyperactive/impulsive symptoms while remaining well tolerated over 30 weeks. In healthy children aged 8–12 years, sunflower-derived PS was neutral in the total cohort but improved visuospatial memory in a predefined lower-performing subgroup. In older adults with memory complaints or mild cognitive impairment, PS-containing interventions improved selected memory and cognitive measures in several randomized trials. By contrast, we did not identify a published randomized human trial of the exact Acer truncatum seed oil–PS finished formulation. Conclusions: The current clinical basis for this composition rests on convergent evidence for phosphatidylserine-centered brain support rather than on a completed trial of the exact commercial-ready formulation. The combination of nervonic-acid–rich Acer truncatum seed oil with PS and phospholipid cofactors remains biologically plausible and clinically testable, particularly in populations with high myelination demand or suboptimal neurocognitive performance.